Overview

Regulatory Hycamtin(Oral) PMS

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of Topotecan administered in Korean patients according to the prescribing information
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Topotecan